CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a...
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a...
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses...
Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at...
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.